Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3,728 Mln
Revenue (TTM)
$31 Mln
Net Profit (TTM)
$-63 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
12.8
Industry P/E
--
EV/EBITDA
-40.2
Div. Yield
0 %
Debt to Equity
0.4
Book Value
$2.8
EPS
$-1
Face value
--
Shares outstanding
114,785,000
CFO
$-511.04 Mln
EBITDA
$-599.12 Mln
Net Profit
$-641.97 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cymabay Therapeu (CBAY)
| 37.5 | 0.8 | 40.7 | 283.5 | 93.5 | 22.2 | 15.8 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Cymabay Therapeu (CBAY)
| 276.7 | 85.5 | -41.1 | 192.9 | -75.1 | -14.4 | 431.8 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cymabay Therapeu (CBAY)
|
32.5 | 3,728.2 | 31.1 | -105.4 | -315.3 | -64.2 | -- | 12.8 |
| 11.1 | 27.8 | 0.1 | -14.8 | -8,225.6 | 252.1 | -- | 5.1 |
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome... proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California. As of March 22, 2024, CymaBay Therapeutics, Inc. operates as a subsidiary of Gilead Sciences, Inc. Read more
President, CEO & Director
Mr. Sujal A. Shah
President, CEO & Director
Mr. Sujal A. Shah
Headquarters
Fremont, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Cymabay Therapeu (CBAY) is $32.48 (NASDAQ) as of 25-Mar-2024 09:30 EDT. Cymabay Therapeu (CBAY) has given a return of 93.54% in the last 3 years.
Since, TTM earnings of Cymabay Therapeu (CBAY) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-23.76
|
8.57
|
|
2022
|
-4.64
|
15.26
|
|
2021
|
-2.59
|
1.81
|
|
2020
|
-8.14
|
2.78
|
|
2019
|
-1.28
|
0.70
|
The 52-week high and low of Cymabay Therapeu (CBAY) are Rs -- and Rs -- as of 03-Apr-2026.
Cymabay Therapeu (CBAY) has a market capitalisation of $ 3,728 Mln as on 25-Mar-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Cymabay Therapeu (CBAY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.